ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...

Among persons at high cardiovascular risk, there is low- to moderate-certainty evidence that reducing or modifying saturated ...

Cancer patients and survivors are more likely to report housing and utility insecurity than those who do not have a history of cancer, according research ...

Sacituzumab govitecan maintained physical functioning scores, contrasting with chemotherapy's deterioration in advanced TNBC patients. Time to deterioration in fatigue was comparable between ...

A meta-analysis showed that reducing saturated fat intake was associated with reduced mortality, albeit only in high-risk ...

The analysis found higher odds of myocardial infarction among e-cigarette users, particularly former smokers, while no ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...

A decade-long investigation of shorter regimens of hypomethylating agents for low-risk myelodysplastic syndrome revealed a ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that the first participants were dosed in the OPUS (OPA-based Pivotal U.S. Study) Phase 3 pivotal, noninferiority trial ...